Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Background ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of autoimmune diseases. We aimed to determine whether ABBV-599 could increase the treatment...

Podrobná bibliografie
Hlavní autoři:	Fleischmann, R, Friedman, A, Drescher, E, Singhal, A, Cortes-Maisonet, G, Doan, T, Lu, W, Wang, Z, Nader, A, Housley, W, Cohen, S, Taylor, PC, Blanco, R
Médium:	Journal article
Jazyk:	English
Vydáno:	Elsevier 2022

Podobné jednotky

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
Autor: Roy Fleischmann, a další
Vydáno: (2024-07-01)

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
Autor: Eyleen de Poel, a další
Vydáno: (2021-09-01)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
Autor: John Mascarenhas, a další
Vydáno: (2023-08-01)

Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study
Autor: Mysler, E, a další
Vydáno: (2021)

The American Thoracic Society’s Spirometric Criteria Alone is Inadequate in Asthma Diagnosis
Autor: John A Gjevre, a další
Vydáno: (2006-01-01)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae.
Autor: Marc P Hübner, a další
Vydáno: (2019-08-01)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Autor: Celeste M. Boesjes, a další
Vydáno: (2023-02-01)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
Autor: Vibeke Strand, a další
Vydáno: (2019-12-01)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
Autor: Vibeke Strand, a další
Vydáno: (2020-06-01)

Construction services welding : examination paper no. 599 /
Autor: City and Guilds of London Institute
Vydáno: ([19-)

Histerectomía laparoscópica en 1 599 pacientes
Autor: Javier Ernesto Barreras González, a další

Transcriptome Analysis of Duck and Chicken Brains Infected with Aquatic Bird Bornavirus-1 (ABBV-1)
Autor: Phuc H. Pham, a další
Vydáno: (2022-10-01)

Upadacitinib for prurigo nodularis
Autor: Clara Muntaner-Virgili, MD, a další
Vydáno: (2024-06-01)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Autor: Fabrice Barlesi, a další
Vydáno: (2021-02-01)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
Autor: Vibeke Strand, a další
Vydáno: (2019-12-01)

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity.
Autor: Thomas W von Geldern, a další
Vydáno: (2019-02-01)

Preponderance of the oncogenic V599E and V599K mutations in <it>B-raf </it>kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases
Autor: Hassanzadeh Judith, a další
Vydáno: (2005-06-01)

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
Autor: John Powderly, a další
Vydáno: (2021-01-01)

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
Autor: Junichiro Yuda, a další
Vydáno: (2023-10-01)

Upadacitinib for the treatment of psoriatic arthritis
Autor: Diogo Fonseca, a další
Vydáno: (2023-02-01)

P599: RARE GERMLINE VARIANTS IN ATM INFLUENCE THE PATHOGENESIS OF CLL
Autor: B. L. Lampson, a další
Vydáno: (2022-06-01)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
Autor: Cesar Rodriguez Valdes, a další
Vydáno: (2023-08-01)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Autor: Joseph F Merola, a další
Vydáno: (2021-11-01)

1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
Autor: Wei Qiu, a další
Vydáno: (2023-11-01)

Effective treatment of alopecia universalis with oral upadacitinib
Autor: Soundos Youssef, MD, a další
Vydáno: (2023-01-01)

Refractory pityriasis rubra pilaris treated with upadacitinib
Autor: Eingun James Song, MD, a další
Vydáno: (2023-05-01)

Correction: Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Vydáno: (2021-12-01)

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report
Autor: Hu W, a další
Vydáno: (2023-10-01)

ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
Autor: Zeynab Fakhar, a další
Vydáno: (2021-01-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
Autor: Alvin F. Wells, a další
Vydáno: (2019-05-01)

Intolerance of aloneness as a prospective predictor of suicidal ideation during COVID-19
Autor: Katie C. Lewis, a další
Vydáno: (2023-01-01)

Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice
Autor: S. Martínez-Fernández, a další
Vydáno: (2023-12-01)

Management outcome(s) in eyes with retinoblastoma previously inadequately treated with systemic chemotherapy alone without focal therapy
Autor: Yacoub A Yousef, a další
Vydáno: (2017-01-01)

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
Autor: Mysler, E, a další
Vydáno: (2022)

US Patent 7,599,807 Compensating for frequency change in flowmeters
Autor: Tombs, M
Vydáno: (2016)

Construction services welding (no.599) : schedules for the in-course assessment of practical work/
Autor: City and Guilds of London Institute
Vydáno: ([19-)

Unilateral blaschkoid lichen planus successfully treated with upadacitinib
Autor: Chiara Rosenbaum, DO, MS, a další
Vydáno: (2024-03-01)

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Vydáno: (2019-06-01)

Case of recalcitrant amyopathic dermatomyositis treated with upadacitinib
Autor: Albert E. Zhou, MD, PhD, a další
Vydáno: (2024-12-01)

Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib
Autor: Axel De Greef, a další
Vydáno: (2024-03-01)